Möchten Sie immer auf dem neuesten Stand bleiben?

Potential breakthrough therapeutic targets $50B+ global immunotherapy market1 CHICAGO, March 31, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a...

WSO2 launches an API Platform to make APIs and AI assets agent-ready, with unified governance, cost control, and no vendor lock-in.

Atlanta, GA, March 31, 2026 (GLOBE NEWSWIRE) -- OfficeSpace Software, provider of the leading AI Operating System for the Built World, today announced it has been named to the Inc. Regionals:...

HSINCHU, Taiwan, March 31, 2026 (GLOBE NEWSWIRE) -- As a global leader in display technologies and solutions, AUO leverages group‑wide strengths to continuously advance deployment across vertical...

First clinical trial conducted in human subjects to evaluate CT2000 for the treatment of both acute ocular pain and chronic ocular surface pain commonly associated with dry eye disease CT2000 is a...

Regula study: outcome-based fraud KPIs are failing. Businesses shift to proactive metrics: compliance, ROI, and real-time fraud detection.

IMNN-001 is the first frontline immunotherapy to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with advanced ovarian cancer Final Phase 2...

ARDS / hypoxemic pneumonia Phase 2 trial initiation 1H 2026; early data by year end; market opportunity of ~200,000–300,000 patients annually in US/EUC-Further Consortium collaboration adds to growing...

TNX-4800 is a long-acting anti-Borrelia burgdorferi OspA human monoclonal antibody in development as a single-dose Lyme prophylactic Phase 1 study of TNX-4800 demonstrated safety, tolerability, and...

Atos expands Lumen Network as a Service across North America data centers to accelerate AI-ready, scalable digital infrastructure.